The rationale for using a DPP-4 inhibitor in our studies was based on its lipid lowering and anti-oxidative properties, and also because many type 2 diabetics have lipid abnormalities like hypercholesterolemia and take this drug to manage their blood glucose. This evidence concerns the gene DPP4 and Hypercholesterolemia.